This study discusses the use of SVF ( Stromal Vascular Fraction).
SVF is the cellular mix obtained from your adipose tissue (body fat). It contains multiple strands of cells inclusive of;
SVF is what we use right here in Macquarie Stem Cells.
In the published literature, the clinical use of systemically administered SVF cells has been reported in two pilot studies. The first was a description of 3 patients suffering from multiple sclerosis who received intravenous administration of SVF as part of a cellular cocktail. All 3 patients reported significant improvement neurologically, and demonstrated an excellent safety profile. Additionally, a patient case report described remission of RA subsequent to administration of autologous SVF.
Let’s take a closer look at the SVF and the abilities
(Rohban and Pieber, 2017) (Fu et al., 2017) (Lauvrud et al., 2016) (Nguyen et al., 2016) (Chen et al., 2016) (Zachar, Bačenková and Rosocha, 2016)
Comparison of immunological properties led to the conclusion that adipose derived MSC appear to have similar properties in terms of suppressing mixed lymphocyte reactions, inhibiting release of type 1 and inflammatory cytokines, as well as generating progeny cells that appear to be relatively immune privileged. These data were confirmed by the group of Zhang et al. who compared cord blood, bone marrow, and adipose MSC and found almost identical ability to inhibit immune response.
Numerous autoimmune conditions enter remission as a result of increased Treg number and/or activity, whereas relapse is associated with reduction in number and/or activity. Specifically, this has been demonstrated in multiple sclerosis, rheumatoid arthritis and lupus. Given the importance of Treg cells in the control of autoimmunity, it would be useful to possess sources of Treg cells that are easily accessible and can be reintroduced into the patient for immune modulation.
It is known that the adipose derived cytokines leptin and TNF-alpha inhibit Treg proliferation and activity. The local effects of these cytokines would conceptually, be negated by liberating Treg from fat tissue followed by systemic re-administration, resulting in enhanced Treg activity.
Thus one conceptual advantage of utilizing SVF therapy would be not only the MSC content, which possesses various regenerative properties, but also Treg, which would enhance anti-inflammatory/tolerance inducing properties. Given that both MSC and Treg are considered to be tolerance-promoting, it may be feasible to consider that synergy of tolerance induction may be occurring when the two cell populations are co-administered in the form of SVF.
Riordan previously reported remission in a patient with rheumatoid arthritis who was treated with autologous SVF. Animal studies using the collagen II model of RA have demonstrated that administration of MSC is associated with immune modulation, disease remission and regeneration of cartilage. Additionally, Riordan’s group and others have reported that Treg cells are associated with induction of disease remission.
Ref:Paz Rodriguez, J., Murphy, M., Hong, S., Madrigal, M., March, K., Minev, B., Harman, R., Chen, C., Timmons, R., Marleau, A. and Riordan, N. (2012). Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety. International Archives of Medicine, 5(1), p.5.
Tags: Macquarie Stem Cells, Dr. Bright, Osteoarthritis Treatment, Dr. Ralph Bright, Stem Cell Therapy, Stem Cell Treatment, Stem Cells for Arthritis